MGTX Stock Analysis: Buy, Sell, or Hold?
MGTX - MeiraGTx Holdings plc Ordinary Shares
$8.09
0.47 (6.17%)
▲
5d:
+5.75%
30d:
+7.01%
90d:
+1.51%
BUY
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Accumulation
MGTX is down 4.1% this week, but smart money is accumulating calls. Top strike: $10 2026-04-17 with 785 OI. Call ratio: 100% View Scanner →
Strength: 7.0/10
Get Alerted When MGTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MGTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: MGTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: MGTX is currently trading at $8.09, which is considered extended relative to its 30-day fair value range of $7.30 to $7.76.
Technical Outlook: Technically, MGTX is in a downtrend. Immediate support is located at $7.01, while resistance sits at $8.56. The stock is showing strong short-term momentum, up 6.2% recently.
Market Sentiment: MGTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $26.25 (+224.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MGTX is in a downtrend. Immediate support is located at $7.01, while resistance sits at $8.56. The stock is showing strong short-term momentum, up 6.2% recently.
Market Sentiment: MGTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $26.25 (+224.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$7.30 -
$7.76
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.2%)
- BULLISH: Trading 224.5% below Wall St target ($26.25)
Fair Price Analysis
30-Day Fair Range
$7.30 -
$7.76
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$7.01
Resistance Level
$8.56
Current Trend
Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.87
Wall Street Target
$26.25
(+224.5%)
Revenue Growth (YoY)
252.3%
Profit Margin
-140.3%
Share & Embed Analysis
Last updated: March 30, 2026 6:23 PM ET
Data refreshes hourly during market hours. Next update: 7:23 PM
Data refreshes hourly during market hours. Next update: 7:23 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MGTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Richard Giroux
SELL
24000 shares
2025-10-21
Alexandria Forbes
SELL
47500 shares
2025-10-07
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 61 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
